Literature DB >> 27342697

Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016).

G B John Mancini1, Steven Baker2, Jean Bergeron3, David Fitchett4, Jiri Frohlich5, Jacques Genest6, Milan Gupta2, Robert A Hegele7, Dominic Ng4, Glen J Pearson8, Janet Pope7, A Yashar Tashakkor5.   

Abstract

The Canadian Consensus Working Group has updated its evaluation of the literature pertaining to statin intolerance and adverse effects. This overview introduces a pragmatic definition of statin intolerance (goal-inhibiting statin intolerance) that emphasizes the effects of symptoms on achieving nationally vetted goals in patients fulfilling indications for lipid-lowering therapy and cardiovascular risk reduction. The Canadian Consensus Working Group provides a structured framework for avoiding, evaluating and managing goal-inhibiting statin intolerance. Particularly difficult practice situations are reviewed, including management in young and elderly individuals, and in athletes and labourers. Finally, targeted at specialty practitioners, more detailed analyses of specific but more unusual adverse effects ascribed to statins are updated including evidence regarding new-onset diabetes, cognitive dysfunction, cataracts, and the rare but important immune-mediated necrotizing myopathy.
Copyright © 2016 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27342697     DOI: 10.1016/j.cjca.2016.01.003

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  51 in total

1.  Hawthorn Extract Alleviates Atherosclerosis through Regulating Inflammation and Apoptosis Related Factors: An Experimental Study.

Authors:  Song-Zi Wang; Min Wu; Ke-Ji Chen; Yue Liu; Jing Sun; Zhuo Sun; He Ma; Long-Tao Liu
Journal:  Chin J Integr Med       Date:  2018-12-05       Impact factor: 1.978

2.  Do Statins Increase the Risk of Esophageal Conditions? Findings from Four Propensity Score-Matched Analyses.

Authors:  Ioana Smith; Robert Schmidt; Ethan A Halm; Ishak A Mansi
Journal:  Clin Drug Investig       Date:  2018-02       Impact factor: 2.859

3.  Value of a Hypothetical Pharmacogenomic Test for the Diagnosis of Statin-Induced Myopathy in Patients at High Cardiovascular Risk.

Authors:  Dominic Mitchell; Jason R Guertin; Jacques LeLorier
Journal:  Mol Diagn Ther       Date:  2018-12       Impact factor: 4.074

4.  A Discrete Event Simulation Model to Assess the Economic Value of a Hypothetical Pharmacogenomics Test for Statin-Induced Myopathy in Patients Initiating a Statin in Secondary Cardiovascular Prevention.

Authors:  Dominic Mitchell; Jason R Guertin; Anick Dubois; Marie-Pierre Dubé; Jean-Claude Tardif; Ange Christelle Iliza; Fiorella Fanton-Aita; Alexis Matteau; Jacques LeLorier
Journal:  Mol Diagn Ther       Date:  2018-04       Impact factor: 4.074

5.  Prevention and management of statin adverse effects: A practical approach for pharmacists.

Authors:  Arden R Barry; Jessica E Beach; Glen J Pearson
Journal:  Can Pharm J (Ott)       Date:  2018-04-04

6.  Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence.

Authors:  Liam R Brunham; Steven Baker; Andrew Mammen; G B John Mancini; Robert S Rosenson
Journal:  Cardiovasc Res       Date:  2018-07-01       Impact factor: 10.787

Review 7.  Coenzyme Q10 as Treatment for Statin-Associated Muscle Symptoms-A Good Idea, but….

Authors:  Amanda L Zaleski; Beth A Taylor; Paul D Thompson
Journal:  Adv Nutr       Date:  2018-07-01       Impact factor: 8.701

Review 8.  Statin-Associated Muscle Adverse Events: Update for clinicians.

Authors:  Maha A Al-Mohaissen; Martha J Ignaszewski; Jiri Frohlich; Andrew P Ignaszewski
Journal:  Sultan Qaboos Univ Med J       Date:  2016-11-30

Review 9.  2017 Position Paper of the Italian Society for Cardiovascular Prevention (SIPREC) for an Updated Clinical Management of Hypercholesterolemia and Cardiovascular Risk: Executive Document.

Authors:  Massimo Volpe; Roberto Volpe; Giovanna Gallo; Vivianne Presta; Giuliano Tocci; Emanuela Folco; Andrea Peracino; Elena Tremoli; Bruno Trimarco
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-05-18

10.  Asprin and statin use for management of atherosclerotic cardiovascular disease in liver transplant candidates: Are we missing the mark?

Authors:  Lisa B VanWagner
Journal:  Liver Transpl       Date:  2018-07       Impact factor: 5.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.